Abstract | Histone deacetylases (HDACs) are considered to be among the most promising targets in drug development for cancer therapy, and first-generation histone deacetylase inhibitors (HDACi) are currently being tested in phase I/II clinical trials. A wide-ranging knowledge of the role of HDACs in tumorigenesis, and of the action of HDACi, has been achieved. However, several basic aspects are not yet fully understood. Investigating these aspects in the context of what we now understand about HDACi action both in vitro and in vivo will further improve the design of optimized clinical protocols.
Histone deacetylases (HDACs) have been intensively scrutinized over the past few years for two main reasons. First, they have been linked mechanistically to the pathogenesis of cancer, as well as several other diseases. Second, small-molecule HDAC inhibitors (HDACi) exist that have the capacity to interfere with HDAC activity and can therefore achieve significant biological effects in preclinical models of cancer. These findings justified the introduction of HDACi into clinical trials. These initial clinical trials have just ended and show encouraging results. At this stage it is crucial to evaluate whether our current knowledge on the mechanisms of tumorigenesis that are linked to HDACs, and on the mechanisms of tumour sensitivity to HDACi, is firm enough to improve the design of further clinical trials. Recent structural and chemical data have emerged that will help in the design of novel HDACi with more desirable properties than the existing ones. However, key areas of investigation that might help to further illuminate the design of successful HDACi-based cancer therapy remain poorly explored. Novel findings indicate that our understanding of how HDACi work will probably change significantly, establishing a new paradigm in the field of intelligent drug design with broad implications for the design of targeted therapies in cancer and possibly other diseases.
HDACs: enzymes looking for substrate(s) Four HDAC classes have been identified (FIG. 1a) . One of them (class 3 or the so-called sirtuins, from the yeast protein Sir2) constitutes a structurally unrelated, NADdependent subfamily, and will not be considered here; neither will the class 3-specific HDACi, which are less characterized than those for the other classes 1 .
An extensive phylogenetic analysis of HDACs has been performed 2, 3 . HDACs are members of an ancient enzyme family found in animals, plants, fungi and bacteria. It is thought that HDACs evolved in the absence of histone proteins. Indeed, eukaryotic HDACs can deacetylate non-histone as well as histone substrates, and some HDACs reside in the cytoplasm (where histones are synthesized and acetylated for proper assembly, without the intervention of HDACs) and in mitochondria (where histones are absent).
Are HDACs, then, truly HDACs 4 ? We postulate that key HDAC substrates might not be histones, but instead belong to the growing list of acetylated non-histone proteins (FIG. 1b and Supplementary information S1 (table)) . Additionally, non-protein molecules such as polyamines or metabolic intermediates might also serve as valid substrates (as found in bacteria).
The search for other substrates, however, should not undervalue the fact that histones (as a bulk mass) are by far the most abundant HDAC substrate, and that histone acetylation surely represents a key target for the action of most HDACs.
The core of the code Histones and DNA constitute the nucleosomes, structural units of chromatin that are essential in packaging eukaryotic DNA. The tail region of the histones (which extend away from the nucleosome core) undergo a complex and coordinated series of regulatory modifications [5] [6] [7] . These modifications can also occur within the globular domain of histones that make extensive contacts with DNA (see FIG. 1c for a list of the known acetylation sites in histones).
It might be oversimplistic to try to assign specific regulatory functions to defined post-translational modifications. The widely used, and in some cases misused, term 'histone code' emphasizes the fact that some chromatin functions are specified by multiple and coordinated histone modifications, and that the same posttranslational modification does not necessarily function in a similar manner in other contexts. However, this rule has many exceptions, to the extent that it seems more appropriate to consider the various post-synthesis modifications of histones as an epigenomic alphabet, in which each modification is a letter, and combined modifications at a defined genomic region constitute a word, which might have different functional meanings in different contexts. Recently, a histone alphabet has been proposed to unify the nomenclature of histone modifications and is based on similar principles 8 . Acetylation (particularly of histone H3 and histone H4 tails) has almost invariably been linked to a chromatin state that is poised for transcription or that corresponds to actively transcribed genomic regions 9 . Therefore, histone acetylases (HATs) and HDACs (acting in the context of multisubunit complexes; BOX 1) have traditionally been linked to activation and repression mechanisms, respectively. Additionally, acetylation of core histones has been correlated with other genome functions, including chromatin assembly, DNA repair and recombination 10, 11 . A crucial role has also been demonstrated for histone acetylation in imposing replication timing of specific genomic regions 12 . In turn, this might lead to large-scale changes in gene expression 13 . In all of these cases, a complex spatio-temporal interplay between HATs and HDACs takes place, which is essential for the correct execution of these events. Many more years of work will be required to further advance our understanding of the role of histone acetylation in the regulation of nuclear events and in the context of the other chromatin modifications.
The rest of the acetylome: new roles for (H)DACs Our knowledge of the non-histone HDAC substrates is rapidly increasing, although it remains fragmented. As for histones, we should view acetylation as part of a complex set of post-translational modifications often working cooperatively to regulate the function of the modified protein(s).
Identifying the entire acetylome deserves a much more aggressive and systematic experimental strategy than has been used so far. A potential approach would be the use of pan-specific antibodies that are able to recognize acetylated lysines in any protein context for proteomic approaches, similar to those used to study other post-translational modifications 14 . These antibodies are available and should produce a dynamic map of the acetylome and its function 15, 16 . A growing list of acetylated proteins is currently available (see Supplementary information S1 (table)). As expected from the cellular localization of HATs and HDACs, both cytoplasmic and nuclear proteins can undergo reversible acetylation. Acetylation of a protein can have many different effects.
Effects on protein stability. Both acetylation and ubiquitylation often occur on the same amino-acid residue (lysine), and there is a direct cross-talk between these two modifications 17 . Competition between acetylation and ubiquitylation influences the stabililty of the substrate and, therefore, indirectly regulates its function. So, HDACs can decrease the half-life of several substrates by exposing the lysine residue for ubiquitylation [18] [19] [20] [21] (FIG. 1b) .
In some cases, the cross-talk is more complex, with both direct and indirect effects (see below).
Effects on protein-protein interactions. In the case of the interferon-β enhanceosome, different HATs acetylate different lysine residues of the structural protein high mobility group protein isoforms I and Y (HMGI/Y, also known as HMGA1) in a precise order. This confers either potentiation of transcriptional activity or destabilization of the enhanceosome and termination of the transcriptional response 22 . In the case of the transcription factor signal transducer and activator of transcription 3 (STAT3), which is activated by cytokine signalling, cytosolic acetylation triggers STAT3 dimerization and subsequent nuclear translocation 23, 24 . Acetylation of hypoxia-inducible factor 1 (HIF1) by the ARD1 HAT apparently leads to increased association with the von Hippel-Lindau (VHL) ubiquitylation complex and proteasome-mediated degradation, which has a regulatory role in the cellular response to changes in oxygen availability and angiogenesis 25, 26 . Another process that is regulated by reversibile acetylation is the cytosolic association of the mainly nuclear DNAdamage-response protein Ku70 (also known as XRCC6)
At a glance
• Histone deacetylases (HDACs) and histone acetylases (HATs) are enzymes that are responsible for deacetylating and acetylating, respectively, the amino-terminal tails of histones. These chromatin changes regulate transcription and many other nuclear events.
• Non-histone proteins (such as the oncosuppressor p53) and several cytoplasmic proteins are also regulated by HATs/HDACs.
• Studies on the molecular pathogenesis of acute myeloid leukaemias have shown that the aberrant recruitment of HDACs has an important role in leukaemogenesis.
• Leukaemia-associated fusion proteins (such as promyelocytic leukaemia (PML)-retinoic acid receptor (RAR) and acute myeloid leukaemia 1 (AML1)-ETO) recruit HDACs to repress the transcription of genes involved in differentiation (the fusion proteins therefore block differentiation) and impair the function of p53.
• Alterations in the expression and/or activity of HATs/HDACs have been also observed in solid tumours. Solid tumours show decreased levels of histone acetylation, which correlates with clinical outcome.
• HDAC inhibitors (HDACi) have been widely studied and belong to several chemical classes.
• HDACi exert cell-type-specific effects inducing apoptosis, cell-cycle arrest, and differentiation.
• In leukaemias, HDACi induce the expression of members of the tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL) and FAS death receptor pathways. This induction is responsible for the pro-apoptotic effects of HDACi.
• Clinical trials for several HDACi have started, and HDACi-responsive tumours have been observed. . B | A schematic view of the functioning acetylome. A partial list of biological processes that are regulated mechanistically by acetylation is sketched in a-j. Acetylation (Ac) might regulate the association of transcription factors (TF -for example, SMAD7, SRBEP, RUNX and ETS) with the DNA (a). Protein stability is also influenced by histone acetyltransferases (HATs) and HDACs, as lysines are subject to both acetylation and ubiquitylation (b). The import and export of proteins into the nucleus is regulated by the acetylation of the importin proteins at the nuclear envelope (c). Multiple, coordinated functions of p53 are known to be regulated by acetylation (d) and accessibility of the nucleosome is another HAT-and HDAC-regulated process (see below) (e). Chaperone functions of heat-shock protein 90 (HSP90) have also been shown to be effected by acetylation. Acetylation of HSP90 in the absence of HDAC6 prevents HSP90 interacting with its target protein (f). The acetylation of signal transducer and activator of transcription 3 (STAT3) induces protein dimerization and translocation to the nucleus (g). The function of the aggresome is regulated by acetylation. HDAC6 is required to properly recruit ubiquitylated proteins to aggresomes, and inhibition of its activity leads to accumulation of polyubiquitylated proteins (h). The translocation of BAX to the mitochondria is influenced by acetylation of the DNAdamage associated protein Ku70. When Ku70 is acetylated, BAX is free to localize to the mitochondria (i). Acetylation also favours nuclear export and cytosolic accumulation of HMG box 1 (HMGB1) before secretion (j). C | The acetylation map of histones. A schematic view of the histone octamer, with the histone tails showing the possible acetylation sites (yellow circles) and methylation sites (blue circles) when this occurs on the same residue. Histone tails undergo a complex, coordinated series of post-translational modifications (phoshorylation, acetylation, methylation, ubiquitylation, ADP-ribosylation, deimination, and probably other post-translational modifications) that are required to regulate chromatin function(s) 6, 7 . Two important mechanisms govern the significance of histone modifications. They can generate docking sites for interaction with additional proteins; bromo-, chromo-and SANT-domains have been shown to recognize specifically modified histones, and to mediate the recruitment of accessory regulatory factors that contain those domains. Also, modifications of histones might affect the condensation state and higher order chromatin structure, owing to their capacity to modulate the exposure of charge patches on the surface of the nucleosomes [5] [6] [7] .
with the pro-apoptotic protein BAX. In its deacetylated form (maintained by several HDACs), Ku70 keeps BAX away from the mitochondrion and protects cells from apoptosis. When the cell is stressed, HATs acetylate Ku70, leading to dissociation of the complex and translocation of BAX to the mitochondria, where it activates the apoptotic programme 27, 28 . Effects on protein localization. As already described for some factors (STAT3 and BAX), reversibile acetylation affects the subcellular localization of several proteins. In some cases, the nuclear localization signal contains acetylatable lysine residues that favour nuclear retention when acetylated 23 . In the case of the multifunctional HMG box 1 (HMGB1) protein, acetylation favours nuclear export and cytosolic accumulation before secretion during inflammatory and/or necrotic processes 29 . Proteins involved in nuclear import can themselves be regulated by acetylation 30 .
Effects on DNA binding. Several transcription factors show increased DNA binding and subsequent transcriptional activity when acetylated, which correlates with the hyper-acetylation of histones in target chromatin (see references in Supplementary information S1 (table) ). Perhaps more surprisingly, in some cases acetylation impairs the binding of transcriptional activators to the DNA, indicating that HATs and HDACs might work in an orchestrated way to achieve the same cellular effect 31 . Interestingly, general transcription factor 2B (GTF2B, also known as TFIIB) has been reported to behave as an auto-acetyltransferase, and acetylation regulates its activity 32 . Acetylation also impairs the catalytic and DNA-binding activities of enzymes involved in DNA metabolism and repair 33, 34 .
Other effects. In some cases, the function of HAT/ HDAC substrates is influenced by acetylation at several levels. The oncosuppressor p53 is regulated by acetylation, which regulates the stability of the protein, its interaction with DNA and its transcriptional activity 35 . Similarly, the DNA-binding affinity of the transcription factor nuclear factor κB (NF-κB) (in its multiple forms) is regulated by HATs/HDACs, as is its transcriptional activation and its association with its regulator, inhibitor of κB-α (IκBα) 36 . Cytoplasmic HDAC6 is crucial for the formation of aggresomes (organelles required for the efficient clearance of misfolded, toxic, cytoplasmic proteins), although in this case the role of protein acetylation remains unclear 37 . Recently, HDAC6 has been shown to deacetylate the cytoplasmic chaperone protein heat-shock protein 90 (HSP90). HSP90 hyperacetylation in HDAC6-deficient cells leads to the loss of chaperone activity 38 . Given the multitude of effects that HDACs have, deciphering the phenotypes of HDAC-deficient model organisms is not always easy. Among class 1 HDACs, only HDAC1 has been knocked out in mammals so far. The phenotype is embryonic lethal at very early stages of development, mainly owing to an arrest of cell growth that is associated with upregulation of the cyclin-dependent-kinase (CDK) inhibitors p21 (also known as WAF1) and p27 (also known as KIP1). This shows a crucial, non-redundant role for HDAC1 in regulating cell proliferation 39 . It is unknown whether the other class 1 HDACs behave similarly. Consistent with their more restricted pattern of expression, class 2 HDAC-knockout mice have demonstrated a crucial role for distinct class 2 HDACs in modulating the growth response of specific tissues such as cartilage and heart muscle. In these cases, association of class 2 HDACs (HDAC5 and HDAC9 in cardiomiocytes and HDAC4 in chondrocytes) with specific transcription factors (MEF2 in heart and RUNX2 in cartilage) leads to repression of genes that are involved in cell growth. Accordingly, the corresponding knockouts show -in contrast to what is observed in Hdac1-null mice -hypertrophic growth 40, 41 . The analysis of HDAC-knockout mice has just started, and we do not precisely understand the cellular responses to the knockout of specific HDACs and how they are dependent on changes in acetylation of histones or of other HDAC substrates. In the case of Hdac1 -/-cells, a general increase in histone acetylation has been observed, pointing to HDAC1 as a crucial component in the control of acetylation. The generation of conditional knockout strains, or the systematic use of RNA interference (RNAi) to knockdown HDAC expression in specific tissues after embryonic development, would also be helpful. Unfortunately, the available HDAC-knockout models have so far not been useful in addressing tumour susceptibility.
HDACs in cancer: a matter of balance
We can expect both positive and negative effects of HDACs on oncogenic and oncosuppressive mechanisms. A balance must exist, and shifts in this balance might have dramatic consequences on the cell phenotype.
Box 1 | Histone deacetylase complexes
A number of histone deacetylase (HDAC)-associated factors and HDACcontaining complexes have been described for class 1 HDACs. HDAC1 and HDAC2 are mainly found associated in the same molecular complexes with Mi2/ NURD (nucleosome remodelling and histone deacetylase), SIN3A and Co-REST, whereas HDAC3 is found in a different complex (the nuclear co-receptor (NCOR)/ silencing mediator for retinoid and thyroid hormone receptors (SMRT) complex) [126] [127] [128] [129] [130] [131] [132] [133] . HDAC6 has been found in cytoplasmic complexes with proteins involved in the ubiquitin signalling pathway 134 . Large multi-enzymatic complexes that contain histone acetyltransferase (HAT) or HDAC have also been described, which might represent the biochemical explanation of the dynamic nature of histone acetylation 135 . Accessory factors might crucially function by 'tethering' the complex to defined genomic regions (looking at chromatin as the main substrate), and to integrate modulatory signals through interactions with other proteins. Apparently, HDACs of different classes can co-exist in the same macromolecular complex. It has been suggested that the HDAC3 complex maintains the enzymatic activity of class 2 HDACs 136 . These studies have been performed by biochemical purification of native complexes or by immunopurification of tagged HDACs (or HDAC-associated factors). These studies were performed in cell lines and cannot be easily reproduced in normal cells, so it remains to be fully understood whether there are differences in the composition of the complexes according to the cell state. The different results reported by various groups might reflect the heterogeneity of the HDACcontaining complexes in different cells at different stages of differentiation.
The most informative evidence on how this balance is altered in cancer cells comes from studies on the pathogenesis of leukaemias 42 . Acute promyelocytic leukaemia (APL) was the first model disease in which the involvement of HDACs was demonstrated 42 . This form of leukaemia is characterized by an arrest of the leukaemic cells at the promyelocytic stage of myeloid differentiation, and is caused (as shown in murine models of the disease) by fusion proteins (found in 100% of patients with APL) of retinoic acid receptor-α (RAR) with one of the following proteins: (in > 95% of cases) promyelocytic leukaemia (PML), (≈ 5% of cases) promyelocytic leukaemia zinc finger (PLZF) or (sporadically) other genes. Clinically, patients with APL (with the exception of patients expressing PLZF-RAR) respond to treatment with pharmacological doses of the RAR ligand, retinoic acid (RA). At the cellular level, the clinical remission is due to the re-initiation of the differentiation programme of the leukaemic cells, which go on to full neutrophilic differentiation and then die, physiologically, by apoptosis 43 . RAR functions as a transcription factor. In the absence of RA, RAR is found at DNA response elements of RA-regulated genes and is associated with HDACcontaining complexes, and this contributes to the transcriptional silencing of these genes. At physiological concentrations of RA, a conformational switch leads to the release of the HDAC-containing complexes and to the association of RAR with transcriptional co-activators (including HATs) and subsequent transcriptional activation. RA target genes are involved in key cellular processes and RAR works in cooperation with several other transcription factors (for example, cytokine-regulated factors such as Stats) 44 to initate transcription. In APL, all fusion proteins maintain the capacity to bind to RA-regulated genes, but share an aberrant feature -physiological concentrations of RA are unable to trigger the switch, and HDACs remain associated to RA targets 45 . To make things worse, RAR fusions oligomerize through self-association domains (present in PML, PLZF and the other genes), which leads to an increased stoichiometric association of HDACcontaining complexes with RA target genes and increased transcriptional silencing 46, 47 . Additionally, recruitment by the fusion protein of other proteins with chromatin modifying activities (DNA methyltransferases and histone methyl-transferases; FIG. 2a) packs the chromatin to an extent that does not allow other physiological stimuli acting on the same genes (that is, cytokines that normally trigger differentiation) to function properly 48, 49 . Although not fully validated experimentally, this model explains most of the observed data. Most importantly, this model fits perfectly with the phenomenon of RA sensitivity (and RA resistance in the case of PLZF-RAR) of patients with APL. In fact, at pharmacological doses of RA (10 to 100-fold higher than physiological doses) the switch is turned on, HDACs dissociate from RAR and the turnover of the fusion proteins (through proteasomal degradation) is significantly increased. These molecular events lead to the powerful differentiative burst of promyelocytes that is seen in treated patients. PLZF-RAR does not respond to RA, even at pharmacological doses, explaining the resistance of patients to RA. However, the combination of RA with HDACi is extremely effective in reactivating RA target genes and triggers a cellular response in vitro and in vivo in PLZF-RAR-positive APL patients 50 . The multiple-hit model hypothesizes that the fusion protein has leukaemogenic potential, but needs to cooperate with one or more additional genetic mutations to trigger the development of leukaemia 51, 52 . The search for these second hits is on, and obvious candidates have been carefully scrutinized. Among these, TP53 mutations are exceedingly rare in patients with APL 53 , but p53 function is compromised through other mechanisms. PML-RAR associates with p53 and along with class 1 HDACs causes its deacetylation and subsequent degradation through the MDM2-proteasome pathway in haematopoietic precursors. These results provide the first link between alterations in p53 acetylation and tumorigenesis, highlighting the relevance of the study of post-translational modifications of non-histone proteins in cancer 54, 55 . Fusion proteins involved in other forms of leukaemia share the capacity to abnormally recruit HDACcontaining complexes 42 . Of course, beyond the apparent similarities, differences do exist. In B-cell lymphomas for example, the oncogene BCL6 encodes a transcriptional repressor that requires HDAC recruitment for its oncogenic properties. Interestingly, BCL6 is negatively regulated through direct acetylation by p300 HAT, and acetylation disrupts its ability to recruit HDACs and to transform cells 56 .
HDACs and HATs in solid tumours
In solid tumours, there is patchy but significant evidence for a disruption in the balance of acetylation and deacetylation (FIG. 2b) . Specific HATs (p300 and CREB (cAMP response element-binding protein)-binding protein (CBP)) are targets of viral oncoproteins (adenoviral E1A, human papilloma virus E6 and the simian virus 40 (SV40) large T antigen) 57 . Monoallelic mutations of both p300 and CBP are found in patients who are affected by the congenital Rubinstein-Taybi syndrome -patients with this syndrome show developmental defects and are prone to cancer 58 . Mutations and inactivations of specific HATs have been observed in a small number of patients with cancer. As for leukaemias, comparable mutations have so far not been observed for HDACs, hinting at the selection of a hyperactive HDAC phenotype in cancer cells 58 . Intriguingly, hyper-expression of HDACassociated factors occurs relatively often; genes of the metastasis-associated protein (Mta) family (in particular, MTA1), are associated with the metastatic phenotype in several tumour types 59 . The mechanistic consequences of overexpressing MTA1 are not well understood. MTA1 associates with the oestrogen receptor and inhibits its function, and in transgenic mice it induces alterations in mammary gland development that lead to tumour formation 60 . MTA1 and other genes are thought to have a crucial function in integrating the enzymatic activity 62 . A more comprehensive analysis of a panel of normal tissues, cancer cell lines and primary tumours has shown a widespread loss of monoacetylated (at K16) and trimethylated (at K20) forms of histone H4 in a large number of tumours 63 . This loss occurs in repetitive DNA sequences and parallels the global loss of DNA methylation in these areas, which is also associated with tumorigenesis 63 . Strikingly, there are clinical correlations between distinct histone modification patterns (modifications examined: histone H3 acetylation at K9 and K18, dimethylation of K4; and histone H4 acetylation at K12, dimethylation at R3) and risk of tumour recurrence in patients with low-grade prostate cancer 64 . Low levels of histone acetylation, which by themselves are not sufficient to draw statistically significant predictions, are correlated with a poorer clinical outcome. Needless to say, a compelling question is whether these changes are restricted to histones or are shared by other HDAC substrates.
Besides histone acetylation, alterations in other epigenetic pathways (not discussed here) clearly have an important role in tumorigenesis. Indirectly, the observation that alterations of other chromatin modifiers can be observed in tumours is an additional link to deregulation in the balance of histone acetylation -both DNA and histone methylation are tightly linked to repressive chromatin states and at least partially dependent on the concomitant action of HDACs [65] [66] [67] . To date, however, the most convincing evidence that HDACs behave differently in cancer cells than in normal cells derives from the pharmacological manipulation of HDACs through HDACi.
Inhibiting HDACs
A dogmatic view of target identification for drug development would indicate that HDACs are not suitable targets -inhibiting HDACs has too many chances of interfering with key cellular functions. Luckily, the use of HDAC inhibitors pre-dated the discovery of the HDACs themselves. In fact, the inhibitors were instrumental in the purification and cloning of mammalian HDACs.
A relatively wide range of structures have been identified that are able to inhibit the activity of class 1, class 2 and class 4 HDACs 68,69 . They derive from both natural sources (FIG. 3a) and from synthetic routes (FIG. 3b) . With a few exceptions, they can all be divided into chemical classes including hydroxamic acid derivatives, carboxylates, benzamides, electrophilic ketones and cyclic peptides 70, 71 . So far, these inhibitors work equally well against class 1, class 2 and class 4 HDACs. Only a few molecules are emerging as preferential inhibitors of class 1 versus recruit histone deacetylases (HDACs) (through co-regulatory (CoR) proteins such as nuclear co-receptor (NCOR)/silencing mediator for retinoid and thyroid hormone receptors (SMRT)) to the promoters of genes containing retinoic acid-responsive elements (RARE), leading to the deacetylation of histones. PML-RAR will then sequentially recruit other chromatin modifiers (DNA methyltransferases DNMT1 and DNMT3a, and the histone H3 K9-methyltransferases SUV39H1 and SUV39H2) that will methylate DNA (CH 3 ) and histones (asterisks). The modified chromatin functions as a docking site for accessory factors that are able to bind methylated DNA (methyl-CpG-binding domain proteins such as MBD1) and methylated histones (such as the heterochromatin associated HP1 protein), thereby leading to the formation of a compact 'heterochromatin-like' structure. Genes that are downregulated by PML-RAR are involved in myeloid differentiation, and because of the action of the fusion protein they become refractory to physiological differentiating stimuli (for example, cytokines and hormones), resulting in the block of differentiation and prolonged proliferation. b | In non-APL cells, other factors (for example, in leukaemias: other fusion proteins such as acute myeloid leukaemia 1(AML1)-ETO; in lymphomas: BCL6; and in solid tumours: deregulated transcription factors) substitute for PML-RAR in targeting HDACs to specific genomic regions, possibly leading to the same or similar set of chromatin alterations observed in APL. The newly formed chromatin structure (directly, or through recruitment of accessory factors) determines an altered pattern of transcription (for coding areas), or of DNA replication or repair, which cooperate in the transformed phenotype. class 2 HDACs, and even fewer (that is, tubacin for HDAC6) are able to discriminate efficiently among HDACs that belong to the same class [72] [73] [74] [75] . At present, this limitation has little relevance to the use of HDACi as potential anti-tumour drugs as there is no definitive evidence that distinct HDACs have a defined role in cancer. On the other hand, HDAC-selective inhibitors would constitute (in addition to genetic tools) a useful experimental tool to address the issue of assigning distinct biological functions to individual HDACs.
From the structure of HDAC8 or HDLP (a HDAClike protein isolated from Aquifex aeolicus), and the structure of these enzymes in complex with a small number of HDACi, a few key points have emerged about the active site that support a pharmacophore model for HDAC inhibition [76] [77] [78] [79] (FIG. 3c) . For the purpose of this review, we will consider -unless specifically mentioned in the text -HDACi as a single entity as they display comparable biological activities. However, they might differ substantially in their pharmacological properties (potency, efficacy, stability and toxicity), and will therefore probably be subject to different degrees of drug development in the future.
The cellular effects of HDACi
HDACi induce, to a variable extent, growth arrest, differentiation or apoptosis in vitro and in vivo 68, 69 . In some cases, growth arrest is induced at low doses, and apoptosis is induced at higher doses; in other cases, growth arrest precedes apoptosis. However, cells might undergo apoptosis without significant changes in their cell-cycle profile. Strikingly, normal cells . In HDACs, the active site of the enzyme (containing the zinc atom) occupies the bottom of a channel delimited by a rim, which corresponds to the substrate pocket (acetyl-lysine). The schematic view of the HDACi 'pharmacophore' (c) therefore consists of: a metal-binding domain (ZnC), which chelates zinc and blocks the enzymatic activity; a linker domain, which mimics the substrate and occupies the enzymatic channel (PCU and HS: polar connecting unit and hydrophobic spacer, respectively); and a surface domain, which makes contacts with the rim 71 . The structures of the HDACi chemical groups that carry out these processes are shown below each of the yellow boxes, as indicated by the arrows.
are almost always considerably more resistant than tumour cells to HDACi 68 . It is worth stressing that there might be HDACidependent pathways that work against the desired anti-proliferation, pro-apoptotic and pro-differentiation effects of HDACi. One such example is the E2F family of transcription factors that regulate target genes that are crucial for S-phase progression. The oncosuppressor retinoblastoma (RB) recruits HDACs to E2F target genes, thereby controlling G1/S cell-cycle progression. HDACi should therefore lead to activation of RB targets, effectively enhancing a key proliferative pathway. Despite these reservations, HDAC recruitment seems crucial only for a subset of RB targets, and cell-cycle regulation by RB proceeds largely through HDACindependent mechanisms 80 . Given the known function of histone acetylation in transcription, it seems logical to postulate that inhibition of HDACs alone is unlikely to lead to a generalized increase in the transcription of all known genes. In fact, acetylation works together with other posttranslational modifications, and blocking deacetylation might have very different outcomes depending on the previous chromatin state. Up to 20% of all known genes are affected by HDACi [81] [82] [83] [84] . Not all of these genes are necessarily upregulated by treatment -the ratio of upregulated to downregulated genes is close to 1:1.
Looking at chromatin as the target for HDACi action, we should not disregard the possibility that HDACi influence other nuclear phenomena besides transcription: what we have previously discussed indicates effects on DNA replication and repair, and both processes can have a key role in modulating the cellular response to HDACi. In fact, HDACi can inhibit DNA repair responses in a few cell lines, which might increase the sensitivity of tumour cells to chemotherapy and radiotherapy by leading to increased DNA damage by these treatments 85, 86 . At least in part, the failure to activate two cell-cycle checkpoints that are present in normal cells is responsible for the tumour-selective action of HDACi 87 . The first is the G2-phase checkpoint, which when defective permits cells to enter an aberrant mitosis. The second is the mitotic-spindle checkpoint, which normally detects aberrant mitosis and blocks mitotic exit until the defect is rectified. The disruption of both checkpoints results in the premature exit of tumour cells from an abortive mitosis and the subsequent induction of apoptosis 88, 89 . One model of action for HDACi derived from these studies, and those on the effects of HDACi on DNA repair, is that HDACi should lead to an increased accumulation of DNA damage (by endogenous stress or by drug treatment) in sensitive cells. As the DNA in these cells will be unrepaired and these defects will remain unchecked owing to the altered cell-cycle checkpoints, this will lead to catastrophic cell death.
Given the pleiotropic effects of HDACs on nonhistone substrates, we must expect additional targets. These targets might be transcription factors themselves, and therefore the ultimate endpoint will eventually be transcriptional (which might help to explain why the transcriptional response to HDACi is so complex). It would be somewhat difficult to ascribe a prominent role to hyper-acetylation of chromatin or transcription factors in the observed response, as these modifications occur concomitantly. A partial dissection of the molecular mechanisms, however, is sometimes possibile. As an example, p21 (see below) is consistently upregulated by HDACi 90 . One of the key transcriptional regulators of p21 is p53. Strikingly, both hyper-acetylation of chromatin at the CDKN1A (which encodes p21) promoter and transcriptional activation of CDKN1A occur at the same level in wild-type and p53-null cells, implying that hyper-acetylation of p53 is not important for the therapeutic efficacy of HDACi (although acetylation of other transcription factors cannot be excluded) 91, 92 . HDACi-mediated acetylation of other substrates might lead to transcriptional effects only indirectly, or work through distinct, nontranscriptional mechanisms. In the end, HDACi might be considered as partially epigenetic drugs.
A complex pattern of HDACi targets must therefore exist that is cell-type-specific, cell-stage-specific, and dependent on the normal or pathological state of the cell. However, some general HDACi-mediated responses are known, and their relevance to the observed cellular effects can be studied. HDACi-induced growth arrest is tightly linked to the induction of p21, and in some cases this arrest has been shown to be irreversible and to resemble the phenomenon of replicative senescence 90, 91, 93 . On the other hand, HDACi also induce cell death through caspase-dependent and caspaseindependent pathways. In most of the studies, caspase activation has been reported to occur through the mitochondria/cytochrome c-mediated apoptotic pathway. Nevertheless, HDACi can induce cell death with morphological features of autophagy in the absence of activated caspases, indicating that HDACi might work in cells with apoptotic defects 94 . In HDACi-induced apoptosis, the mitochondrion and the production of pro-apoptotic reactive oxygen species (ROS) seems to be important [94] [95] [96] . The precise mechanisms underlying the accumulation of ROS are under investigation and might help us to understand why normal cells are selectively resistant to HDACi treatment. Normal, but not transformed, human fibroblasts accumulate thioredoxin (TXN, also known as TRX), a natural ROS scavenger, after treatment with HDACi. Therefore, ROS accumulation might be neutralized in normal cells by TXN, whereas transformed cells die because they do not express TXN: indeed, knockdown of TXN in normal cells causes accumulation of ROS and increased cell death 96 . Interestingly, Bax -/-murine embryonic fibroblasts are also resistant to HDACi 97 . As discussed earlier, hyper-acetylation of cytoplasmic Ku70 causes the activation of BAX and apoptosis 97 . HDACi also cause hyper-acetylation of HSP90 and its inactivation, leading to the degradation of proteins that require the chaperone function of HSP90 (including some oncoproteins 98, 99 100 . A limitation of these observations is their lack of systematic analysis, the use of cell lines as model systems -which do not necessarily reflect the biology of primary tumour cells -and the focus on a limited number of HDACi.
As a well-defined model system, APL offers an interesting paradigm for studying HDACi action (FIG. 4) . HDACi trigger apoptosis of APL cells both in vitro and in murine models of the disease 101, 102 . An obvious explanation for this effect would be the reversal of the HDAC-dependent action of the fusion protein, as discussed earlier in this review. Strikingly, however, HDACi function in APL through a fusion-protein-independent and p53-independent mechanism (see below). But, in appropriate experimental conditions, such as on the induction of cellular stress, HDACi can revert the leukaemic cell phenotype through an effect on the RAR fusion proteins 55 . However, this effect is not necessary for the anticancer effects of HDACi.
On the right TRAIL HDACi induce hyper-acetylation of the promoters of several members of the death receptor pathway including TRAIL (tumour-necrosis factor-related apoptosis-inducing ligand) and its receptor, death receptor 5 (DR5), and FAS ligand (FASL) and FAS, through a mechanism that seems to involve acetylation of the transcription factors SP1 or SP3, and subsequent recruitment of CBP. RNAi-based studies performed in vitro and in vivo show that these genes are uniquely required for the induction of apoptosis in leukaemic cells, both from APL mice and freshly isolated leukaemic blasts from patients who do not have APL. Intriguingly, not all blasts respond to HDACi by undergoing apoptosis, and these cases do not show induction of TRAIL or FAS pathways 54, 102 . The reasons for this lack of response are unknown. Preliminary evidence indicates that HDACi might activate components of the death receptor pathways in various solid tumours. In fact, in several cases HDACi synergize with exogenously added TRAIL to induce apoptosis of tumour cell lines [103] [104] [105] [106] . However, the effect on the death receptor pathway is not universal, and therefore its activation does not necessarily represent an obligate path for HDACi-mediated cell death.
In conclusion, many areas of investigation on the biological effects of HDACi show an exciting and complex network of cellular responses, coupling transcriptional and non-transcriptional effects. It is difficult at this stage to predict the existence of a universal, key cellular target that is responsible for the HDACi-mediated response. To try to address this question, it would be helpful to analyse systematically, and in different model systems, all of the proposed effectors of HDACi to define their relative contributions to the observed biological effects. In the absence of such studies, we can only speculate whether the different mechanisms that have been proposed represent cell-type-specific responses to HDACi, or whether the simultaneous activation of several pathways (or all of them required for maximal effect) have a synergistic function.
An encouraging observation is that in several cases normal cells show a strikingly reduced sensitivity to HDACi treatment, hinting at potentially large differences in the acetylome in normal versus tumour cells that can be exploited clinically.
HDACi in clinical development
The first studies on the clinical use of HDACi have been published recently [107] [108] [109] . These studies are phase I/II trials, and their endpoint is therefore somewhat limited (the main aim being to analyse/exclude unwanted toxicity and to find optimal doses/schedules), although one of the objectives of phase II studies is to measure the clinical response. It is not our scope to review in detail single studies on specific HDACi, but rather to draw initial and very preliminary conclusions, and to suggest how such trials need to evolve (TABLE 1) .
These reports generally confirm the initial impression from preclinical studies of low toxicity of HDACi in patients, if compared with most of the currently used anti-tumour treatments. The toxic effects of HDACi, which vary based on the class of HDACi used, might at least in part be the result of the non-specific side effects of each individual HDACi rather than the consequences of inhibiting HDAC per se. In fact, some of these compounds are only efficacious at high concentrations in which interference with additional targets would probably be responsible for toxicity. As for most 
Maximal tolerated dose
The maximal dosage of a particular drug that can be used before patients show undesired side effects. chemotherapic drugs, bone marrow toxicity (of low to moderate degreee) is often observed. Strikingly, in some cases the maximal tolerated dose or MTD has not been reached in clinical trials, implying that specific HDACi have minimal toxicity and a wide therapeutic window (TABLE 1) .
Unfortunately, the relationship between the toxicity of HDACi and their pharmacodynamic/pharmacokinetic properties is still largely unknown. This makes it difficult to optimize HDACi treatment. In particular, we do not know which patients are most likely to respond to HDACi. Naively, we would predict that HDACi might be useful only in those tumours in which HDACs are directly involved in the pathogenesis. However, in light of the effects of HDACi in murine models of leukaemia, we anticipate that HDACi might be useful in other contexts as they might attack tumour-cell-specific targets that are not directly involved in tumorigenesis. We also do not know the key target(s) for HDACi action. Proposed surrogate markers, such as measuring the levels of acetylated histones from peripheral blood cells before and after treatment 16 , should serve as indicators of effectiveness, but these need to be validated clinically and do not always seem to correlate strictly with pharmacokinetic profiles 110, 111 . Alternative strategies could be attempted to identify novel predictive markers; gene profiling studies from tumour samples obtained from responders and nonresponders might lead to their identification. Also, we do not know whether there is a requirement for continuous inhibition of HDACs to achieve the maximal effect. Studies in preclinical models (such as leukaemias) have shown that an intraperitoneal injection of HDACi induces pulses of histone hyper-acetylation in tumour cells (lasting a few hours), followed by a return to basal levels. This response is owing to the fast degradation of the HDACi used in those studies, which resemble the kinetics and fast degradation of many HDACi (particularly those based on hydroxamic acid) in the human bloodstream. In mice, this treatment regimen leads to rapid and massive apoptosis of tumour cells, with little toxicity observed. Are we happy with this observation and to use it as a benchmark for a similar response in patients? Although a clinical response is observed in the mouse models (and in patients treated with HDACi -see below), animals are not cured, and as soon as the treatment is stopped, the disease kills them in 100% of the cases. It seems plausible that the continuous inhibition of HDAC activity will have a more positive long-term response, but will it also be more toxic for normal cells? Two different formulations of the same drug (oral and intravenous suberoylanilide hydroxamic acid (SAHA)) apparently confirm this trend. Oral SAHA has a more favourable pharmacokinetic profile (half-life of 120 minutes versus 40 minutes for intravenous SAHA) and results in a better clinical performance, but it is substantially more toxic 111, 112 . HDACi with substantially longer half-lives (such as MS-275, with a half-life of up to 80 hours) show a higher toxicity that precludes daily treatment 113 . Valproic acid is being taken at high doses by epileptic patients with no side effects, but this HDACi has an extremely low potency and most of the absorbed drug (up to 90%) is bound to serum proteins, making it unlikely to significantly inhibit HDACs at the doses used in these patients. Notwithstanding these caveats, promising results have been observed in terms of clinical response in the current trials. None of the HDACi tested in clinical trials is completely without clinical effect, confirming that HDACs represent a promising target for further development. The results have been especially good in patients with T-cell cutaneous lymphoma, and in some cases a long-term response has been observed 114, 115 . The molecular basis for this response is being explored in vitro 116 . Tumour regression (in some cases quite dramatic) has also been observed in solid tumours 111, 112 . Acquired resistance to HDACi has been reported anecdotally, implying that it might be a clinically rare event 117 . Depsipeptide has been reported to be a substrate for P-glycoprotein (Pgp, also known as ATP-binding cassette subfamily B, member 1 (ABCB1)), and multidrug resistance-associated protein 1 (MRP1, also known as ABCC1), and to induce Pgp expression, indicating that resistance to HDACi might be drug-specific 116, 118 . Systematic in vitro studies have explored the possibility that HDACi might synergize with other drugs 109 . The effect of a wide spectrum of chemotherapeutic drugs is potentiated by HDACi, but the mechanistic basis for this synergy has not been fully explored. Given the results previously discussed, one way to increase sensitivity to chemotherapy and/or radiotherapy would be the suppression of checkpoint and repair mechanisms triggered by induced DNA-damage. Unfortunately, synergism in efficacy might be accompanied by adverse effects that are rarely or never seen with HDACi alone, and caution should be employed when considering clinical studies that address HDACi in combination with other therapies. Clinical studies combining RA treatment with HDACi are in progress in patients with leukaemia, expecially in the elderly 119 . Of particular interest is the combination of HDACi with other drugs acting on epigenetic mechanisms. DNA-demethylating agents in combination with HDACi show potent responses in vitro and they are also being tested in clinical trials 120 . The combination of HDACi with DNA-demethylating agents should be more carefully analysed in murine models of tumours, with a view to optimizing the design of clinical studies. HDACi might also work synergistically with HSP90 inhibitors; this would further inhibit the capacity of HSP90 to chaperone oncoproteins that are required for the survival of tumour cells 121 .
Perspectives
The prevailing conclusion is one of excitement for our progress in understanding the function of HDACs in tumour pathogenesis and the tumour response to HDACi, and hope for the exploitation of this knowledge to develop more effective clinical protocols.
There are areas that we have not covered that might become relevant in the future. For instance, the regulation of HDAC enzymatic activity through post-translational modifications (phosphorylation or sumoylation) could turn out to be very important in modulating HDAC function. This could potentially be exploited pharmacologically 122 . Another issue to be considered is that, so far, there is no conclusive experimental evidence that points to specific HDACs as being selectively involved in any form of disease, including cancer. A systematic analysis to try to identify selective HDACi that will enable the study of specific HDACs is mandatory if we are to develop potentially less toxic and more effective treatments. There are other areas that we have discussed above that also require urgent answers.
A more general consideration also needs to be addressed. It has becoming increasingly clear that tumour cells are not homogeneous and that cancer stem cells exist 123, 124 . It is reasonable to assume that the failures of current cancer therapy are in part due to the failure to target cancer stem cells. HDACi affect the maintenance of stem-cell potential in CD34 + human haematopoietic progenitors in vitro 125 . So far, no study using HDACi (either preclinical or clinical) has addressed the crucial issue of tumour stem-cell sensitivity, which should be clarified as soon as possible to verify the true potential of HDACi in clinical treatment.
Perhaps, an epigenetic (or partially epigenetic) therapy for cancer (the 'epi-cure') is getting closer.
